RE:FULL DATA RELEASERon, someone in the Q&A in the conference call asked why -0.4 plaque regression was used as primary endpoint. Don said the BOD and the scientists came up with -0.6. They felt that was an obtainable number. 0.3+ would still be a success but they would have had to double the number of people in the study at minimum and extend the length of the trial. They didnt have the money to do that. Each patient in the 6 month study cost $50k+ each.